Clinical Trial: A Real-World Study of Early Breast Cancer Patients Eligible for Treatment With CDK4/6 Inhibitors

U.S., June 16 -- ClinicalTrials.gov registry received information related to the study (NCT07647042) titled 'A Real-World Study of Early Breast Cancer Patients Eligible for Treatment With CDK4/6 Inhibitors' on June 09.

Brief Summary: The aim of this study was to describe treatment patterns, patient characteristics and clinical outcomes among hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) early breast cancer (eBC) patients who became eligible for treatment with cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) in the real-world setting after the FDA approval of ribociclib treatment for eBC.

The study used data abstracted from structured and unstructured patient electronic health records from site...